Wegovy® is a weight management injection developed by Novo Nordisk, a Danish pharmaceutical company. Its active ingredient is semaglutide, a medicine that belongs to the GLP-1 class.

GLP-1 is a natural hormone released by the gut after eating. Semaglutide works in a similar way by helping to slow down how quickly food leaves the stomach and by acting on areas of the brain involved in appetite control. This may help you feel fuller sooner, reduce hunger, and lower overall calorie intake.

Treatment results vary from person to person. On average, people using Wegovy® may lose around 10%–15% of their body weight.

Before starting Wegovy®, a doctor’s consultation is required to review your health condition and assess whether this treatment is suitable for you. Depending on your medical history, additional tests may also be required.

Wegovy® | GLP-1 Receptor Agonist | Semaglutide | Weight Loss Pen | 100% Authentic

Name: Wegovy® | GLP-1 Receptor Agonist | Semaglutide | Weight Loss Pen | 100% Authentic
SKU: FM-WEGOV-PEN-PARENT

HK$2,899.00

選擇劑量

Quantity

0.25mg:HK-67962
0.5mg:HK-67963
1mg:HK-67964
1.7mg:HK-67965
2.4mg:HK-67966
Who may be suitable for Wegovy®?

Wegovy® may be suitable for adults who:

Have a BMI ≥ 30; or

Have a BMI ≥ 27 with at least one weight-related health condition;

Have tried different weight management methods without satisfactory results;

Have limited time or ability to plan diet and exercise routines;

Tend to have a large appetite, cravings, or frequent snacking habits;

Experience postnatal weight gain, middle-aged weight gain, or reduced metabolism.

A doctor’s assessment is required before use to determine whether Wegovy® is suitable for your health condition.

Who may not be suitable for Wegovy®?

Wegovy® may not be suitable for people who:

Have had an allergic reaction to semaglutide or other GLP-1 receptor agonists;

Have severe digestive system diseases;

Are pregnant or breastfeeding;

Have a history of severe acute pancreatitis;

Have severe liver or kidney impairment or failure;

Have Medullary Thyroid Carcinoma (MTC) or a personal/family history of MTC;

Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Please consult a doctor before using Wegovy® to assess suitability and safety.
Wegovy® is injected once weekly and can be used at any time of the day. However, it is recommended to inject it at a consistent time each week. It is not affected by meal times.

Wegovy® is a subcutaneous injection. The recommended injection areas are the front of the abdomen, the outer thigh, or the upper arm.

Prepare the injection pen: Take out the injection pen, check that the solution is clear and free from particles, then attach a new needle.

Set the dose: Turn the dose selector to the dose instructed by your doctor.

Clean the injection site: Use an alcohol swab to clean the injection area.

Inject the medication: Insert the needle vertically into the skin and press the button until the indicator window shows that the injection is complete.

Hold for a few seconds: Keep the needle under the skin for around 6 seconds after injection to ensure the full dose has been delivered.

Dispose of the needle: Remove the used needle immediately after use and dispose of it properly in a sharps container.
Wegovy® is a prescription medication and may cause the following common side effects, which are usually mild and more common during the initial adjustment period:

Nausea or vomiting

Diarrhoea or constipation

Dizziness or tiredness

Reduced appetite

Mild redness or swelling at the injection site

These symptoms usually appear at the beginning of treatment. As the body adjusts to the medication, most users may find that the symptoms gradually improve.

Rare but serious side effects may involve gallbladder disease or pancreatitis. Therefore, close monitoring is required during treatment, and medical advice should be sought promptly when needed.

If you experience any side effects, especially if the symptoms are severe or persistent, please consult your doctor.